
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is positioned for success with their innovative TrueMRD test, expanding portfolio of cancer diagnostic tests, and strong financial performance. Their recent acquisition and development of new tests show their dedication to providing effective solutions for cancer diagnoses. With a projected mid-teens growth rate and potential for further growth, Veracyte's stock has a positive outlook for long-term investors.
Bears say
Veracyte is a genomic diagnostics company that offers several tests for different types of cancer. Despite strong revenue growth in the testing segment and a positive free cash flow, the company's reliance on a few key product lines, such as Decipher and Afirma, leaves it vulnerable to a potential decline in demand. Additionally, the company's Biopharmaceutical Services revenue declined significantly in the most recent quarter, indicating a lack of diversification in its revenue streams.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares